Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal disorders characterized by dysplastic hematopoietic cells, ineffective hematopoiesis, and a variable risk of transformation to acute myeloid leukemia (AML) with few curative therapeutic options. Recent studies have established that genes encoding spliceosomal proteins are the most common mutational targets in MDS, with ~60% of MDS patients harboring a spliceosomal gene mutation. These spliceosomal mutations occur exclusively in a heterozygous context, are mutually exclusive with one another, and frequently co-occur with mutations affecting specific epigenetic regulators. However, the molecular and biological reasons for this distinctive mutational pattern are not known, nor is it understood how spliceosomal mutations contribute to dysplastic hematopoiesis. Here, we propose to determine the genetic basis as well as mechanistic and phenotypic consequences of mutations affecting the spliceosomal gene SRSF2. Our team consists of a physician-scientist with experience in MDS biology and patient care (Abdel-Wahab) and a basic scientist with expertise in RNA splicing and genomics (Bradley). In preliminary studies, we found that SRSF2 mutations result in impaired hematopoiesis and altered exon recognition, and we generated extensive novel reagents to explore the functional importance of SRSF2 mutations. We propose to build on these preliminary studies as follows:
Aim 1, Determine how SRSF2 mutations alter SFSF2's normal role in pre-mRNA splicing to promote myelodysplasia;
Aim 2, determine the biological and molecular basis for the association between SRSF2 mutations and additional genetic alterations;
Aim 3, Identify and test therapeutic strategies for targeting malignant cells with SRSF2 mutations. The significance of these studies is that they will definitively connect SRSF2 mutations to altered RNA splicing mechanisms and dysplastic hematopoiesis. The health relatedness is that our studies may identify new therapeutic opportunities for MDS by selectively targeting cells carrying SRSF2 mutations.
Myelodysplastic syndromes (MDS) are blood disorders that are characterized by abnormal and dysfunctional blood cell production. Currently there are no curative therapeutic options for the majority of MDS patients, and there is therefore great interest in developing novel therapeutic strategies based on an improved understanding of the molecular basis of MDS. Recently, mutations affecting the gene SRSF2 were discovered to be very common in MDS and related diseases. However, it remains unclear how these mutations affect the normal function of SRSF2 protein, how these mutations contribute to disease, and whether cells carrying these mutations may be vulnerable to new therapeutic approaches. We propose to study SRSF2 mutations using a variety of molecular and genetic techniques in order to further our understanding of MDS pathogenesis and identify potential new therapeutic opportunities.
|Papo, Matthias; Diamond, Eli L; Cohen-Aubart, Fleur et al. (2017) High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 130:1007-1013|
|Durham, Benjamin H; Roos-Weil, Damien; Baillou, Claude et al. (2017) Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 130:176-180|
|Yoshimi, Akihide; Abdel-Wahab, Omar (2017) Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. Clin Cancer Res 23:336-341|
|Taylor, Justin; Xiao, Wenbin; Abdel-Wahab, Omar (2017) Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood 130:410-423|
|Joshi, Poorval; Halene, Stephanie; Abdel-Wahab, Omar (2017) How do messenger RNA splicing alterations drive myelodysplasia? Blood 129:2465-2470|
|Durham, Benjamin H; Getta, Bartlomiej; Dietrich, Sascha et al. (2017) Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood 130:1644-1648|
|Yoshimi, Akihide; Balasis, Maria E; Vedder, Alexis et al. (2017) Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood 130:397-407|
|Micol, Jean-Baptiste; Pastore, Alessandro; Inoue, Daichi et al. (2017) ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun 8:15429|
|Ntziachristos, Panagiotis; Abdel-Wahab, Omar; Aifantis, Iannis (2016) Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol 17:1016-24|
|Inoue, Daichi; Abdel-Wahab, Omar (2016) Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities. Cancer Cell 30:371-373|
Showing the most recent 10 out of 15 publications